GlycoMimetics Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Total Funding:$95M
Industry:Pharma
Founded:2003
Lead Investor(s):Jefferies, Cowen
Press
Claim your profile

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • GlycoMimetics's estimated annual revenue is currently $8.4M per year.
  • GlycoMimetics received $119.0M in venture funding in March 2018.
  • GlycoMimetics's estimated revenue per employee is $153,491
  • GlycoMimetics's total funding is $95M.

Employee Data

  • GlycoMimetics has 55 Employees.
  • GlycoMimetics grew their employee count by -5% last year.
  • GlycoMimetics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Advarra
$52.1M25929%N/A
Correct Rx Phar...
$16.5M82-6%N/A
ISPE
$78.4M390N/AN/A
Factor One Sour...
$7.2M3629%N/A
Ascentage Pharm...
$17.1M8529%N/A
United Therapeu...
N/A806N/AN/A
Pharmaceutics I...
$51.5M256N/AN/A
SilcsBio
$1M5N/AN/A
India Globaliza...
N/A12N/AN/A
Rexahn Pharmace...
N/A15N/AN/A
Missing a competitor? Contribute!?
Submit

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow's breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company's inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

55

Number of Employees

$8.4M

Revenue (est)

1

Current Jobs

-5%

Employee Growth %

$95M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Rachel KingCEOEmail Available
John MagnaniCso, Senior Vp And Co-founderEmail Available
Radhika ParikhDirector, Clinical Project ManagementEmail Available
Armand GirardSenior Vice President, Strategy And Corporate DevelopmentEmail Available
Scott ShapotDirector, Regulatory AffairsEmail Available
Martina HemmerDirector, Clinical OperationsEmail Available
Arun SarkarDirector of ChemistryEmail Available
Carol CulwellManager of AccountingEmail Available
Stephanie IrishDirector, Accounting And ReportingEmail Available
David EntinDirector, Corporate Contracts, Licensing And Business DevelopmentEmail Available

GlycoMimetics News

09/03/2019 - Form SC 13G/A GLYCOMIMETICS INC Filed by ...

UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549. SCHEDULE 13G. (Rule 13d-102). INFORMATION ...

09/08/2019 - What's Behind the Numbers For GlycoMimetics, Inc ...

The Price to Book ratio for GlycoMimetics, Inc. NasdaqGM:GLYC is 0.841807. The Price to book ratio is the current share price of a company ...

09/03/2019 - Allianz Asset Management GmbH Lowers Stake in ...

Allianz Asset Management GmbH lowered its stake in shares of GlycoMimetics Inc (NASDAQ:GLYC) by 12.0% during the 2nd quarter, ...

GlycoMimetics Funding

DateAmountRoundLead InvestorsReference
2003-05-23$4.3M1stNew Enterprise AssociatesArticle
2004-08-06$9.6MAAlliance Technology Ventures, Anthem Capital ManagementArticle
2006-06-26$15.4MUndisclosedNew Enterprise AssociatesArticle
2009-10-21$38.0MUndisclosedGenzyme Ventures, New Enterprise AssociatesArticle
2016-06-20$18.6MUndisclosedJefferies LLCArticle
2017-05-25$92.6MUndisclosedJefferies LLCArticle
2018-03-21$119.0MUndisclosedJefferiesArticle

GlycoMimetics Executive Hires

DateNameTitleReference
2012-01-06Helen ThackrayChief Medical OfficerArticle
2014-04-24Armand GirardVP Corporate DevelopmentArticle
2017-06-13Patricia AndrewsCEOArticle